State Street SPDR S&P Biotech ETF

Frequently Asked Questions About XBI

What does XBI invest in?

SPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.

What is the expense ratio of XBI?

State Street SPDR S&P Biotech ETF (XBI) charges an expense ratio of 0.35%. This is the annual fee deducted from fund assets to cover management and operations.

How big is XBI?

State Street SPDR S&P Biotech ETF (XBI) manages $10.24B in total assets. AUM determines bid-ask liquidity and the fund's vulnerability to closure — funds below ~$50M are at higher risk of liquidation.

Is XBI actively managed or an index fund?

XBI is a passive index fund — it tracks a published benchmark by holding the constituents in their published weights. Index funds typically charge low expense ratios (XBI's is 0.35%) because there's no security selection cost.

When was XBI launched?

State Street SPDR S&P Biotech ETF (XBI) launched in January 2006 and is managed by SPDR.

How has XBI performed?

XBI's total return — price change plus reinvested distributions — is charted at the top of this page. Switch the price chart to Total Return and pick a 1-year, 3-year, 5-year, or 10-year window to read the compound annual growth rate (CAGR) over each horizon.